RyMed Wins Jury Trial Over ICU's Valve Patent
The jury found that ICU failed to prove that RyMed's InVision-Plus product literally infringed a claim of U.S. Patent No. 5,685,866.
RyMed spokesman Paul Blackburn said the verdict confirms RyMed’s longstanding belief that it hasn't infringed ICU’s patent.
“Of course we’re absolutely thrilled,” Blackburn told Law360. “It’s been a long time coming, and it...
To view the full article, register now.